1. Home
  2. RLMD vs RPD Comparison

RLMD vs RPD Comparison

Compare RLMD & RPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

HOLD

Current Price

$7.07

Market Cap

784.6M

Sector

Health Care

ML Signal

HOLD

Logo Rapid7 Inc.

RPD

Rapid7 Inc.

HOLD

Current Price

$6.27

Market Cap

780.5M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
RLMD
RPD
Founded
2004
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
784.6M
780.5M
IPO Year
2012
2015

Fundamental Metrics

Financial Performance
Metric
RLMD
RPD
Price
$7.07
$6.27
Analyst Decision
Strong Buy
Hold
Analyst Count
5
21
Target Price
$12.40
$15.50
AVG Volume (30 Days)
1.4M
2.0M
Earning Date
05-11-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
45.28
N/A
EPS
N/A
0.36
Revenue
$13,070.00
$685,083,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$0.54
P/E Ratio
N/A
$17.57
Revenue Growth
154.83
N/A
52 Week Low
$0.27
$4.97
52 Week High
$7.94
$27.10

Technical Indicators

Market Signals
Indicator
RLMD
RPD
Relative Strength Index (RSI) 55.77 54.83
Support Level $3.49 $5.92
Resistance Level $7.41 $7.17
Average True Range (ATR) 0.44 0.41
MACD -0.07 0.19
Stochastic Oscillator 35.01 75.58

Price Performance

Historical Comparison
RLMD
RPD

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

About RPD Rapid7 Inc.

Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.

Share on Social Networks: